DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder

Information source: Osaka City University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: SSRI-Refractory Obsessive-Compulsive Disorder

Intervention: atypical antipsychotic drug (Drug); exposure response prevention (Behavioral)

Phase: Phase 4

Status: Completed

Sponsored by: Osaka City University


Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OCD) in short terms trials, there are few data on the effectiveness and safety of these agents in clinical settings over the long term. Method: Subjects (n=46) who responded to selective SRIs (SSRIs) in an initial 12-week trial were continued on SRI-monotherapy plus cognitive-behavioral therapy (CBT) for one year. Subjects (n=44) who failed to respond to SSRIs were randomly assigned to one of 3 AAPDs such as risperidone and were consecutively treated using SSRI+AAPD combined with CBT for a year.

Clinical Details

Official title: An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder

Study design: N/A

Primary outcome: Yale-Brown Obsessive-Compulsive Scale

Secondary outcome:

yale-Brown Obsessive-Compulsive Scale


Detailed description: More recently, second-generation atypical antipsychotic drugs (AAPD) that modulate both 5-HT and DA function, such as risperidone (RIS), olanzapine (OLZ) and quetiapine (QET), have been found effective in the augmentation of SSRIs for treatment-resistant OCD. Nevertheless, the AAPDs have been associated with common and serious adverse effects, such as body weight (BW) gain and metabolic dysregulation. Metabolic dysregulation includes glucoregulatory dysfunction and dyslipidemia. Indeed, studies of some AAPD in SSRI-refractory OCD patients have similarly reported significant BW gain. AAPD-induced BW gain may influence patients' adherence to medication and places them at risk for a broad range of medical problems. Most work on AAPDs in treatment-refractory OCD has been conducted in the form of short-term efficacy studies. There have been fewer studies of the effectiveness, safety, and tolerability of these agents in the context of a clinic where CBT is also provided, and where treatment is continued for a significant period of time. In the current effectiveness study, we sought to examine the response of SSRI-refractory patients to augmentation with AAPDs, comparing adverse events in such compared to a control group of SSRI responders.


Minimum age: 20 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Male or female, 18 years of age or over

- Patients were diagnosed as having obsessive-compulsive disorder by the Structured

Clinical Interview for DSM-IV Patient version (SCID-P)

- They received standardized treatment for at least 1 year at the OCD clinic in our

university hospital.

- Each subject gave written informed consent to take part after receiving a complete

description of this study.

- All subjects were free of medical illness based on results of physical examination

and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period. Exclusion Criteria:

- Current clinically significant medical conditions such as diabetes

Locations and Contacts

Dept of Neuropsychiatry, Osaka City University, graduate School of Medicine, Osaka 545-8585, Japan
Additional Information

Starting date: January 2006
Last updated: March 2, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017